ChemoCentryx Regains Crohn’s Candidate Vercirnon From GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK will continue development of a rheumatoid arthritis candidate optioned from ChemoCentryx in 2011 and is expected to decide before year’s end on whether to license a Phase II candidate for renal vasculitis from the California biotech.
You may also be interested in...
GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.
Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
EU Business News: PharmaSGP Makes Record Start, BioGaia Heads To Canada, Ardian Takes Nutripure Stake
Round-up of European consumer health business news: Germany's PharmaSGP breaks sales record in Q1 as acquired brands grow; probiotics player BioGaia plans direct distribution in Canada; and private-equity firm Ardian takes a stake in French e-commerce supplements specialist Nutripure.